Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | SENP1 | Q9P0U3 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 2/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31094018 | 1.00 | LMNA (0.43) | LMNAHPGDHIF1ACA1CA2 | |
| SCHEMBL5316055 | 1.00 | LMNA (0.43) | LMNAHPGDHIF1ACA1CA2 | |
| SCHEMBL437193 | 1.00 | LMNA (0.43) | LMNAHPGDHIF1ACA1CA2 | |
| SCHEMBL480558 | 0.94 | HIF1A (0.44) | LMNAHPGDHIF1ACA1CA2 | |
| SCHEMBL480555 | 0.94 | HIF1A (0.44) | LMNAHPGDHIF1ACA1CA2 | |
| SCHEMBL2573759 | 0.93 | HIF1A (0.42) | LMNAHPGDHIF1ACA1CA2 | |
| SCHEMBL2573754 | 0.93 | HIF1A (0.42) | LMNAHPGDHIF1ACA1CA2 | |
| SCHEMBL3157262 | 0.93 | MAPT (0.48) | LMNASENP1NPC1RAB9AKMT2A | |
| SCHEMBL3157274 | 0.93 | MAPT (0.48) | LMNASENP1NPC1RAB9AKMT2A | |
| SCHEMBL480886 | 0.92 | LMNA (0.47) | LMNAHPGDHIF1ACA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12533313-B2 | Inhalable liposomal sustained release composition for use in treating pulmonary diseases | INSPIRMED CORP. (TW) | 2026-01-27 | — | — | US | claimed |
| US-20230088661-A1 | INHALABLE LIPOSOMAL SUSTAINED RELEASE COMPOSITION FOR USE IN TREATING PULMONARY DISEASES | INSPIRMED CORP (TW) | 2023-03-23 | — | — | US | claimed |
| EP-3643309-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | Boehringer Ingelheim International GmbH (DE) | 2020-04-29 | — | — | EP | claimed |
| US-20160136133-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2016-05-19 | — | — | US | claimed |
| EP-2878297-A1 | Medicaments for the treatment or prevention of fibrotic diseases | Boehringer Ingelheim International GmbH (DE) | 2015-06-03 | — | — | EP | claimed |
| EP-2826480-A1 | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis | Boehringer Ingelheim International GmbH (DE) | 2015-01-21 | — | — | EP | claimed |
| US-20140296217-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-10-02 | — | — | US | claimed |
| EP-2409705-A1 | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-25 | — | — | EP | claimed |
| EP-2384751-A1 | Medicaments for the treatment or prevention of fibrotic diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-09 | — | — | EP | claimed |
| EP-2361626-A1 | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-31 | — | — | EP | claimed |
| EP-1830843-A2 | INDOLIDONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | Boehringer Ingelheim International GmbH (DE) | 2007-09-12 | — | — | EP | claimed |
| US-20060142373-A1 | Medicaments for the Treatment or Prevention of Fibrotic Diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-06-29 | — | — | US | claimed |
| WO-2006067165-A2 | INDOLIDONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-06-29 | — | — | WO | claimed |
| EP-1530466-A2 | USE OF LCK INHIBITOR FOR TREATMENT OF IMMUNOLOGIC DISEASES | Boehringer Ingelheim Pharma KG (DE) | 2005-05-18 | — | — | EP | claimed |
| US-20050043233-A1 | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-02-24 | — | — | US | claimed |
| US-20040204458-A1 | Use of Lck inhibitors for treatment of immunologic diseases | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-10-14 | — | — | US | claimed |
| US-6762180-B1 | Substituted indolines which inhibit receptor tyrosine kinases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-07-13 | — | — | US | claimed |
| WO-2004017948-A2 | USE OF LCK INHIBITOR FOR TREATMENT OF IMMUNOLOGIC DISEASES | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-03-04 | — | — | WO | claimed |
| EP-1224170-A1 | 6-POSITION SUBSTITUTED INDOLINE, PRODUCTION AND USE THEREOF AS A MEDICAMENT | Boehringer Ingelheim Pharma KG (DE) | 2002-07-24 | — | — | EP | claimed |
| WO-2001027081-A1 | 6-POSITION SUBSTITUTED INDOLINE, PRODUCTION AND USE THEREOF AS A MEDICAMENT | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2001-04-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12533313-B2 | Inhalable liposomal sustained release composition for use in treating pulmonary diseases | ADRM1, ALK, AGK | LMNA 568/4885HPGD 3832/4885HIF1A 1318/4885 |
| US-20060142373-A1 | Medicaments for the Treatment or Prevention of Fibrotic Diseases | MMP1, COL1A1, FOXM1 | LMNA 222/4885HPGD 215/4885HIF1A 706/4885 |
| US-20160136133-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | MMP1, COL1A1, FOXM1 | LMNA 222/4885HPGD 215/4885HIF1A 706/4885 |
| US-20140296217-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | MMP1, COL1A1, FOXM1 | LMNA 222/4885HPGD 215/4885HIF1A 706/4885 |
| US-20050043233-A1 | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis | BAX, BCL2, CXCL12 | LMNA 1029/4885HPGD 347/4885HIF1A 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.